Noonan Syndrome-Associated SHP2/PTPN11 Mutants Cause EGF-Dependent Prolonged GAB1 Binding and Sustained ERK2/MAPK1 Activation

Alessandra Fragale, Marco Tartaglia, Jie Wu, Bruce D. Gelb

Research output: Contribution to journalArticle

Abstract

Noonan syndrome is a developmental disorder with dysmorphic facies, short stature, cardiac defects, and skeletal anomalies, which can be caused by missense PTPN11 mutations. PTPN11 encodes Src homology 2 domain-containing tyrosine phosphatase 2 (SHP2 or SHP-2), a protein tyrosine phosphatase that acts in signal transduction downstream to growth factor, hormone, and cytokine receptors. We compared the functional effects of three Noonan syndrome-causative PTPN11 mutations on SHP2's phosphatase activity, interaction with a binding partner, and signal transduction. All SHP2 mutants had significantly increased basal phosphatase activity compared to wild type, but that activity varied significantly between mutants and was further increased after epidermal growth factor stimulation. Cells expressing SHP2 mutants had prolonged extracellular signal-regulated kinase 2 activation, which was ligand-dependent. Binding of SHP2 mutants to Grb2-associated binder-1 was increased and sustained, and tyrosine phosphorylation of both proteins was prolonged. Coexpression of Grb2-associated binder-1-FF, which lacks SHP2 binding motifs, blocked the epidermal growth factor-mediated increase in SHP2's phosphatase activity and resulted in a dramatic reduction of extracellular signal-regulated kinase 2 activation. Taken together, these results document that Noonan syndrome-associated PTPN11 mutations increase SHP2's basal phosphatase activity, with greater activation when residues directly involved in binding at the interface between the N-terminal Src homology 2 and protein tyrosine phosphatase domains are altered. The SHP2 mutants prolonged signal flux through the RAS/mitogen-activated protein kinase (ERK2/MAPK1) pathway in a ligand-dependent manner that required docking through Grb2-associated binder-1 (GAB1), leading to increased cell proliferation.

Original languageEnglish
Pages (from-to)267-277
Number of pages11
JournalHuman Mutation
Volume23
Issue number3
DOIs
Publication statusPublished - 2004

Fingerprint

Non-Receptor Type 11 Protein Tyrosine Phosphatase
Noonan Syndrome
Epidermal Growth Factor
Mitogen-Activated Protein Kinase 1
Signal Transduction
SH2 Domain-Containing Protein Tyrosine Phosphatases
Ligands
Somatotropin Receptors
Mutation
Cytokine Receptors
Protein Tyrosine Phosphatases
Growth Factor Receptors
Missense Mutation
Phosphoric Monoester Hydrolases
Tyrosine
Phosphorylation
Cell Proliferation
Proteins

Keywords

  • Epidermal growth factor
  • ERK2
  • GAB1
  • MAPK1
  • Mitogen-activated protein kinase
  • Noonan syndrome
  • NS
  • PTPN11
  • SHP-2
  • SHP2
  • Signal transduction

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Noonan Syndrome-Associated SHP2/PTPN11 Mutants Cause EGF-Dependent Prolonged GAB1 Binding and Sustained ERK2/MAPK1 Activation. / Fragale, Alessandra; Tartaglia, Marco; Wu, Jie; Gelb, Bruce D.

In: Human Mutation, Vol. 23, No. 3, 2004, p. 267-277.

Research output: Contribution to journalArticle

@article{0f47c4c7c1844677810a36c8d8aa3ab2,
title = "Noonan Syndrome-Associated SHP2/PTPN11 Mutants Cause EGF-Dependent Prolonged GAB1 Binding and Sustained ERK2/MAPK1 Activation",
abstract = "Noonan syndrome is a developmental disorder with dysmorphic facies, short stature, cardiac defects, and skeletal anomalies, which can be caused by missense PTPN11 mutations. PTPN11 encodes Src homology 2 domain-containing tyrosine phosphatase 2 (SHP2 or SHP-2), a protein tyrosine phosphatase that acts in signal transduction downstream to growth factor, hormone, and cytokine receptors. We compared the functional effects of three Noonan syndrome-causative PTPN11 mutations on SHP2's phosphatase activity, interaction with a binding partner, and signal transduction. All SHP2 mutants had significantly increased basal phosphatase activity compared to wild type, but that activity varied significantly between mutants and was further increased after epidermal growth factor stimulation. Cells expressing SHP2 mutants had prolonged extracellular signal-regulated kinase 2 activation, which was ligand-dependent. Binding of SHP2 mutants to Grb2-associated binder-1 was increased and sustained, and tyrosine phosphorylation of both proteins was prolonged. Coexpression of Grb2-associated binder-1-FF, which lacks SHP2 binding motifs, blocked the epidermal growth factor-mediated increase in SHP2's phosphatase activity and resulted in a dramatic reduction of extracellular signal-regulated kinase 2 activation. Taken together, these results document that Noonan syndrome-associated PTPN11 mutations increase SHP2's basal phosphatase activity, with greater activation when residues directly involved in binding at the interface between the N-terminal Src homology 2 and protein tyrosine phosphatase domains are altered. The SHP2 mutants prolonged signal flux through the RAS/mitogen-activated protein kinase (ERK2/MAPK1) pathway in a ligand-dependent manner that required docking through Grb2-associated binder-1 (GAB1), leading to increased cell proliferation.",
keywords = "Epidermal growth factor, ERK2, GAB1, MAPK1, Mitogen-activated protein kinase, Noonan syndrome, NS, PTPN11, SHP-2, SHP2, Signal transduction",
author = "Alessandra Fragale and Marco Tartaglia and Jie Wu and Gelb, {Bruce D.}",
year = "2004",
doi = "10.1002/humu.20005",
language = "English",
volume = "23",
pages = "267--277",
journal = "Human Mutation",
issn = "1059-7794",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Noonan Syndrome-Associated SHP2/PTPN11 Mutants Cause EGF-Dependent Prolonged GAB1 Binding and Sustained ERK2/MAPK1 Activation

AU - Fragale, Alessandra

AU - Tartaglia, Marco

AU - Wu, Jie

AU - Gelb, Bruce D.

PY - 2004

Y1 - 2004

N2 - Noonan syndrome is a developmental disorder with dysmorphic facies, short stature, cardiac defects, and skeletal anomalies, which can be caused by missense PTPN11 mutations. PTPN11 encodes Src homology 2 domain-containing tyrosine phosphatase 2 (SHP2 or SHP-2), a protein tyrosine phosphatase that acts in signal transduction downstream to growth factor, hormone, and cytokine receptors. We compared the functional effects of three Noonan syndrome-causative PTPN11 mutations on SHP2's phosphatase activity, interaction with a binding partner, and signal transduction. All SHP2 mutants had significantly increased basal phosphatase activity compared to wild type, but that activity varied significantly between mutants and was further increased after epidermal growth factor stimulation. Cells expressing SHP2 mutants had prolonged extracellular signal-regulated kinase 2 activation, which was ligand-dependent. Binding of SHP2 mutants to Grb2-associated binder-1 was increased and sustained, and tyrosine phosphorylation of both proteins was prolonged. Coexpression of Grb2-associated binder-1-FF, which lacks SHP2 binding motifs, blocked the epidermal growth factor-mediated increase in SHP2's phosphatase activity and resulted in a dramatic reduction of extracellular signal-regulated kinase 2 activation. Taken together, these results document that Noonan syndrome-associated PTPN11 mutations increase SHP2's basal phosphatase activity, with greater activation when residues directly involved in binding at the interface between the N-terminal Src homology 2 and protein tyrosine phosphatase domains are altered. The SHP2 mutants prolonged signal flux through the RAS/mitogen-activated protein kinase (ERK2/MAPK1) pathway in a ligand-dependent manner that required docking through Grb2-associated binder-1 (GAB1), leading to increased cell proliferation.

AB - Noonan syndrome is a developmental disorder with dysmorphic facies, short stature, cardiac defects, and skeletal anomalies, which can be caused by missense PTPN11 mutations. PTPN11 encodes Src homology 2 domain-containing tyrosine phosphatase 2 (SHP2 or SHP-2), a protein tyrosine phosphatase that acts in signal transduction downstream to growth factor, hormone, and cytokine receptors. We compared the functional effects of three Noonan syndrome-causative PTPN11 mutations on SHP2's phosphatase activity, interaction with a binding partner, and signal transduction. All SHP2 mutants had significantly increased basal phosphatase activity compared to wild type, but that activity varied significantly between mutants and was further increased after epidermal growth factor stimulation. Cells expressing SHP2 mutants had prolonged extracellular signal-regulated kinase 2 activation, which was ligand-dependent. Binding of SHP2 mutants to Grb2-associated binder-1 was increased and sustained, and tyrosine phosphorylation of both proteins was prolonged. Coexpression of Grb2-associated binder-1-FF, which lacks SHP2 binding motifs, blocked the epidermal growth factor-mediated increase in SHP2's phosphatase activity and resulted in a dramatic reduction of extracellular signal-regulated kinase 2 activation. Taken together, these results document that Noonan syndrome-associated PTPN11 mutations increase SHP2's basal phosphatase activity, with greater activation when residues directly involved in binding at the interface between the N-terminal Src homology 2 and protein tyrosine phosphatase domains are altered. The SHP2 mutants prolonged signal flux through the RAS/mitogen-activated protein kinase (ERK2/MAPK1) pathway in a ligand-dependent manner that required docking through Grb2-associated binder-1 (GAB1), leading to increased cell proliferation.

KW - Epidermal growth factor

KW - ERK2

KW - GAB1

KW - MAPK1

KW - Mitogen-activated protein kinase

KW - Noonan syndrome

KW - NS

KW - PTPN11

KW - SHP-2

KW - SHP2

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=1542619343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542619343&partnerID=8YFLogxK

U2 - 10.1002/humu.20005

DO - 10.1002/humu.20005

M3 - Article

C2 - 14974085

AN - SCOPUS:1542619343

VL - 23

SP - 267

EP - 277

JO - Human Mutation

JF - Human Mutation

SN - 1059-7794

IS - 3

ER -